Use of natural products as chemical library for drug discovery and network pharmacology

PLoS One. 2013 Apr 25;8(4):e62839. doi: 10.1371/journal.pone.0062839. Print 2013.

Abstract

Background: Natural products have been an important source of lead compounds for drug discovery. How to find and evaluate bioactive natural products is critical to the achievement of drug/lead discovery from natural products.

Methodology: We collected 19,7201 natural products structures, reported biological activities and virtual screening results. Principal component analysis was employed to explore the chemical space, and we found that there was a large portion of overlap between natural products and FDA-approved drugs in the chemical space, which indicated that natural products had large quantity of potential lead compounds. We also explored the network properties of natural product-target networks and found that polypharmacology was greatly enriched to those compounds with large degree and high betweenness centrality. In order to make up for a lack of experimental data, high throughput virtual screening was employed. All natural products were docked to 332 target proteins of FDA-approved drugs. The most potential natural products for drug discovery and their indications were predicted based on a docking score-weighted prediction model.

Conclusions: Analysis of molecular descriptors, distribution in chemical space and biological activities of natural products was conducted in this article. Natural products have vast chemical diversity, good drug-like properties and can interact with multiple cellular target proteins.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Biological Products / pharmacology*
  • Computational Biology
  • Databases, Pharmaceutical*
  • Disease
  • Drug Approval
  • Drug Discovery / methods*
  • Pharmacology / methods*
  • United States
  • United States Food and Drug Administration / legislation & jurisprudence

Substances

  • Biological Products

Grants and funding

The present work was supported by the Major Scientific and Technological Special Project for ‘Significant New Drugs Formulation’ number 2012ZX09501001; 012ZX09301002-001 (http://www.most.gov.cn). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.